Skip to main content

Table 2 Univariate analysis of survival-related characteristics in HG-SOCs

From: Nadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer

Variable

PFS (OR, 95% CI)

OS (OR, 95% CI)

MDACC

JICR

MDACC

JICR

FIGO stage

 I

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 II

1.11 (0.44–2.81)

1.27 (0.63–3.95)

1.31 (0.45–3.77)

1.62 (0.65–3.99)

 III

2.66 (1.25–5.66)

4.19 (1.97–9.64)

3.65 (1.56–9.17)

4.79 (2.26–10.14)

 IV

3.03 (1.37–6.70)

6.57 (3.05–13.69)

5.38 (2.20–13.20)

7.03 (3.28–15.05)

Ascites

 No

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 Yes

1.73 (1.22–2.47)

1.93 (1.52–2.42)

1.92 (1.42–2.60)

2.04 (1.61–2.58)

Residual tumors

 No

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 Yes

1.54 (1.10–2.14)

1.68 (1.15–2.40)

1.99 (1.63–2.63)

2.10 (1.67–2.56)

Neo-chemotherapy

 Yes

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 No

1.38 (1.01–1.95)

1.45 (1.14–1.78)

1.33 (0.40–3.56)

1.12 (0.84–1.60)

Chemotherapy, including paclitaxel

 Yes

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 No

1.01 (0.82–1.47)

1.12 (1.00–1.44)

1.30 (0.41–4.10)

1.18 (0.80–1.63)

CA-125, decreasing kinetics

 ≥1/32

1.00 (reference)

1.00 (reference)

1.00 (reference)

1.00 (reference)

 <1/32

1.12 (1.06–1.47)

1.50 (1.23–1.85)

1.17 (0.62–2.27)

1.09 (0.67–2.21)

Baseline CA-125

1.02 (1.01–1.06)

1.03 (1.01–1.06)

1.03 (1.01–1.05)

1.06 (1.02–1.10)

CA-125 level at relapse

1.01 (1.00–1.01)

1.01 (1.00–1.02)

1.01 (1.00–1.01)

1.01 (1.00–1.13)

Nadir CA-125

1.04 (1.02–1.08)

1.06 (1.02–1.09)

1.02 (1.01–1.04)

1.04 (1.01–1.07)